GlassScriptPhysician profile
Ahmed Hussein
NPI 1104294685
$31,381.21
in general payments reported to CMS, 2019-2025
15 companies · $695 in 2025
The $695 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.86 · 2022: $192 · 2023: $291 · 2024: $30K · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $25K · Travel and Lodging: $3,278 · Food and Beverage: $2,844 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $25,000.00 |
| Travel and Lodging | $3,278.43 |
| Food and Beverage | $2,843.87 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $26,306.92 | 2022-2024 | Versacross Access Solution, Lux-Dx Insertable Cardiac Monitor, Avvigo Guidance System |
| Edwards Lifesciences Corporation | $2,355.75 | 2021-2025 | Pascal, Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $1,246.46 | 2024-2025 | Mitraclip, Amplatzer |
| Abiomed | $1,058.32 | 2022-2025 | Impella |
| Pfizer INC. | $91.28 | 2022-2025 | |
| Medtronic, INC. | $67.35 | 2022 | |
| Amgen INC. | $39.36 | 2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $38.32 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $35.89 | 2022-2023 | Farxiga |
| Chiesi USA, INC. | $35.57 | 2023 | Kengreal, Cleviprex |
| E.R. Squibb & Sons, L.L.C. | $26.88 | 2023 | Camzyos |
| Bridgebio Pharma, INC. | $24.13 | 2025 | Attruby |
| Astellas Pharma US INC | $21.44 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.65 | 2025 | |
| Alnylam Pharmaceuticals INC. | $15.89 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Hussein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.